STOCK TITAN

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Meridian Bioscience, Inc. (NASDAQ: VIVO) announced its participation in the 2022 H.C. Wainwright Global Investment Conference. CEO Jack Kenny will pre-record a presentation, available on their website starting May 24, 2022, and accessible for 90 days. Meridian specializes in diagnostic testing solutions and life science raw materials, serving over 70 countries. Their products address various health concerns, including gastrointestinal infections and blood lead level testing. For more details on the conference, visit www.hcwevents.com/globalconference/.

Positive
  • None.
Negative
  • None.

CINCINNATI, May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H.C. Wainwright Global Investment Conference.  Jack Kenny, Chief Executive Officer, will pre-record the company's presentation.  A link to Mr. Kenny's presentation will be posted on May 24, 2022, on the Meridian Bioscience website at https://investor.meridianbioscience.com/news-events/events-presentations/, and will be accessible for 90 days.

For additional information on the 2022 H.C. Wainwright Global Investment Conference, please visit www.hcwevents.com/globalconference/

About Meridian Bioscience, Inc.  
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian's shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

Contact:  
Charlie Wood  
Vice President – Investor Relations  
Meridian Bioscience, Inc.  
Phone:  +1 513.271.3700  
Email: mbi@meridianbioscience.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/meridian-bioscience-to-participate-in-the-2022-hc-wainwright-global-investment-conference-301553073.html

SOURCE Meridian Bioscience, Inc.

FAQ

When is Meridian Bioscience participating in the H.C. Wainwright Global Investment Conference?

Meridian Bioscience is participating in the 2022 H.C. Wainwright Global Investment Conference on May 23, 2022.

What will Jack Kenny present at the conference?

Jack Kenny, CEO of Meridian Bioscience, will pre-record a presentation for the conference.

Where can I watch the Meridian Bioscience conference presentation?

The presentation will be available on Meridian Bioscience's website starting May 24, 2022.

How long will the Meridian Bioscience presentation be available to view?

The presentation will be accessible for 90 days after it goes live on May 24, 2022.

What does Meridian Bioscience specialize in?

Meridian Bioscience specializes in diagnostic testing solutions and life science raw materials.

VIVO

NASDAQ:VIVO

VIVO Rankings

VIVO Latest News

VIVO Stock Data

1.49B
43.35M
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Cincinnati